News

DUBLIN, March 1, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington D.C. March 1-5, 2019.

The meeting will be held at the Walter E. Washington Convention Center and the scheduled times (noted in local Eastern Time) for the Allergan presentations are as follows:

Oral Poster Presentations

Botulinum Neurotoxin Type A Directly Affects Sebocytes and Inhibits Induced Lipogenesis

• Authors: Hui You, Alex Chernavsky, Sergei Grand, Amy Brideau-Andersen, Birgitte Jacky
• Friday, 3/1: 10:00-10:05AM, Hall H, ePoster Presentation Center 1

Protective and Reparative Effects of a Topical Dual Serum System Against UV-Induced Skin Damage

• Authors: Elizabeth Makino, Pricilla Tan, Rahul C. Mehta
• Saturday, 3/2: 9:45-9:50AM, Hall H, ePoster Presentation Center 1

Environmental protection and rejuvenation from a novel antioxidant dual serum system: A randomized, double-blind, regimen controlled, multi-center study

• Authors: Zoe D. Draelos, Elizabeth Makino, Priscilla Tan, Kuniko Kadoya, Audrey Nguyen, Lily Jiang, Rahul C. Mehta
• Sunday, 3/3: 9:10-9:15AM, Hall D, ePoster Presentation Center 2

Poster Presentations

Botulinum Neurotoxin Type A Exhibits a Linear Correlation Between Dose, Peak Efficacy and Duration of Effect in Functional Assays

• Authors: Greg S. Nicholson, Dave Canty, Amy D. Brideau-Andersen and Ron S. Broide
• Available for online viewing during program

Safety and Efficacy of OnabotulinumtoxinA for Treatment of Masseter Muscle Hypertrophy: Results from a Phase 2 Dose-Escalation Study

• Authors: Jean Carruthers, Steven Liew, Jason K Rivers, Shyi-Gen Chen, Shannon Humphrey, Elisabeth Lee, Beta Bowen, Mitchell F. Brin
• Available for online viewing during program

Clinical Efficacy of a Novel Two-Part Skincare System on Pollution-Induced Skin Damage

• Authors: Elizabeth T. Makino, Annie Jain, Priscilla Tan, Audrey Nguyen, Alain Mogac, Kuniko Kadoya
• Available for online viewing during program

Evaluation of the Protective Effect of a Topical Serum Against Particles Modeling Atmospheric Pollution

• Authors: Elizabeth Makino, Pricilla Tan, Cécile Charmel, Rahul C. Mehta
• Available for online viewing during program

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.